These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 17565496)
1. 99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule. Engfeldt T; Tran T; Orlova A; Widström C; Feldwisch J; Abrahmsen L; Wennborg A; Karlström AE; Tolmachev V Eur J Nucl Med Mol Imaging; 2007 Nov; 34(11):1843-53. PubMed ID: 17565496 [TBL] [Abstract][Full Text] [Related]
2. (186)Re-maSGS-Z (HER2:342), a potential Affibody conjugate for systemic therapy of HER2-expressing tumours. Orlova A; Tran TA; Ekblad T; Karlström AE; Tolmachev V Eur J Nucl Med Mol Imaging; 2010 Feb; 37(2):260-9. PubMed ID: 19771426 [TBL] [Abstract][Full Text] [Related]
3. Development and preclinical characterisation of 99mTc-labelled Affibody molecules with reduced renal uptake. Ekblad T; Tran T; Orlova A; Widström C; Feldwisch J; Abrahmsén L; Wennborg A; Karlström AE; Tolmachev V Eur J Nucl Med Mol Imaging; 2008 Dec; 35(12):2245-55. PubMed ID: 18594815 [TBL] [Abstract][Full Text] [Related]
4. Effects of lysine-containing mercaptoacetyl-based chelators on the biodistribution of 99mTc-labeled anti-HER2 Affibody molecules. Tran TA; Ekblad T; Orlova A; Sandström M; Feldwisch J; Wennborg A; Abrahmsén L; Tolmachev V; Eriksson Karlström A Bioconjug Chem; 2008 Dec; 19(12):2568-76. PubMed ID: 19035668 [TBL] [Abstract][Full Text] [Related]
5. Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence. Engfeldt T; Orlova A; Tran T; Bruskin A; Widström C; Karlström AE; Tolmachev V Eur J Nucl Med Mol Imaging; 2007 May; 34(5):722-733. PubMed ID: 17146656 [TBL] [Abstract][Full Text] [Related]
6. Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine. Ahlgren S; Wållberg H; Tran TA; Widström C; Hjertman M; Abrahmsén L; Berndorff D; Dinkelborg LM; Cyr JE; Feldwisch J; Orlova A; Tolmachev V J Nucl Med; 2009 May; 50(5):781-9. PubMed ID: 19372467 [TBL] [Abstract][Full Text] [Related]
7. Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties. Wållberg H; Orlova A; Altai M; Hosseinimehr SJ; Widström C; Malmberg J; Ståhl S; Tolmachev V J Nucl Med; 2011 Mar; 52(3):461-9. PubMed ID: 21321280 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of a HER2-targeting affibody molecule combining an N-terminal HEHEHE-tag with a GGGC chelator for 99mTc-labelling at the C terminus. Lindberg H; Hofström C; Altai M; Honorvar H; Wållberg H; Orlova A; Ståhl S; Gräslund T; Tolmachev V Tumour Biol; 2012 Jun; 33(3):641-51. PubMed ID: 22249974 [TBL] [Abstract][Full Text] [Related]
10. Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors. Orlova A; Nilsson FY; Wikman M; Widström C; Ståhl S; Carlsson J; Tolmachev V J Nucl Med; 2006 Mar; 47(3):512-9. PubMed ID: 16513621 [TBL] [Abstract][Full Text] [Related]
11. (99m)Tc-maEEE-Z(HER2:342), an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors. Tran T; Engfeldt T; Orlova A; Sandström M; Feldwisch J; Abrahmsén L; Wennborg A; Tolmachev V; Karlström AE Bioconjug Chem; 2007; 18(6):1956-64. PubMed ID: 17944527 [TBL] [Abstract][Full Text] [Related]
12. Preclinical Evaluation of Oroujeni M; Rinne SS; Vorobyeva A; Loftenius A; Feldwisch J; Jonasson P; Chernov V; Orlova A; Frejd FY; Tolmachev V Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33803361 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of 99mTc-peptide-ZHER2:342 Affibody® molecule for in vivo molecular imaging. Zhang JM; Zhao XM; Wang SJ; Ren XC; Wang N; Han JY; Jia LZ Br J Radiol; 2014 Jan; 87(1033):20130484. PubMed ID: 24273251 [TBL] [Abstract][Full Text] [Related]
14. Monitoring therapeutic response of human ovarian cancer to trastuzumab by SPECT imaging with (99m)Tc-peptide-Z(HER2:342). Zhang J; Zhao X; Wang S; Wang N; Han J; Jia L; Ren X Nucl Med Biol; 2015 Jun; 42(6):541-6. PubMed ID: 25735223 [TBL] [Abstract][Full Text] [Related]
15. Influence of DOTA chelator position on biodistribution and targeting properties of (111)In-labeled synthetic anti-HER2 affibody molecules. Perols A; Honarvar H; Strand J; Selvaraju R; Orlova A; Karlström AE; Tolmachev V Bioconjug Chem; 2012 Aug; 23(8):1661-70. PubMed ID: 22768790 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of [(111/114m)In]CHX-A''-DTPA-ZHER2:342, an affibody ligand coniugate for targeting of HER2-expressing malignant tumors. Orlova A; Rosik D; Sandström M; Lundqvist H; Einarsson L; Tolmachev V Q J Nucl Med Mol Imaging; 2007 Dec; 51(4):314-23. PubMed ID: 17464277 [TBL] [Abstract][Full Text] [Related]
17. 188Re-ZHER2:V2, a promising affibody-based targeting agent against HER2-expressing tumors: preclinical assessment. Altai M; Wållberg H; Honarvar H; Strand J; Orlova A; Varasteh Z; Sandström M; Löfblom J; Larsson E; Strand SE; Lubberink M; Ståhl S; Tolmachev V J Nucl Med; 2014 Nov; 55(11):1842-8. PubMed ID: 25278516 [TBL] [Abstract][Full Text] [Related]
18. Influence of an aliphatic linker between DOTA and synthetic Z(HER2:342) Affibody molecule on targeting properties of the (111)In-labeled conjugate. Tolmachev V; Feldwisch J; Lindborg M; Baastrup B; Sandström M; Orlova A Nucl Med Biol; 2011 Jul; 38(5):697-706. PubMed ID: 21718945 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of 99mTc-Z IGF1R:4551-GGGC affibody molecule, a new probe for imaging of insulin-like growth factor type 1 receptor expression. Mitran B; Altai M; Hofström C; Honarvar H; Sandström M; Orlova A; Tolmachev V; Gräslund T Amino Acids; 2015 Feb; 47(2):303-15. PubMed ID: 25425114 [TBL] [Abstract][Full Text] [Related]